Mohammad Alhaji, MD
Nephrology · Novi, MINPI 1053627570
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,603 of the $16,655 with a category attached, or 81.7%. Bayer accounts for 85.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $8,926 and has fallen 98.6% since, to $122 in 2025. Among nephrology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $346.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$14K
- AstraZeneca$2K
- Boehringer Ingelheim$123
- GSK$118
- AMAG Pharmaceuticals, Inc.$108
- Pharmacosmos Therapeutics Inc.$106
- plus $191 from 6 others
What the payments were for
- Consulting fees$1,60010%
- Speaking & faculty fees$13,60382%
- Food & beverage$1,4068%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 19 | $14,186 |
| AstraZeneca | 11 | $1,823 |
| Boehringer Ingelheim | 5 | $123 |
| GSK | 1 | $118 |
| AMAG Pharmaceuticals, Inc. | 1 | $108 |
| Pharmacosmos Therapeutics Inc. | 1 | $106 |
| Novartis | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Vifor Pharma, Inc. | 2 | $27 |
| Shionogi Inc | 1 | $25 |
| Akebia Therapeutics Inc | 1 | $25 |
| Novo Nordisk | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$13,973
- LOKELMA$1,710
- BENLYSTA$118
- FERAHEME$108
- Monoferric$106
How this compares
$16,655 in reported general payments places this provider in the 90th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 175 | $176,149 |
| JardianceEmpagliflozin | 101 | $122,806 |
| KerendiaFinerenone | 16 | $21,766 |
| MyrbetriqMirabegron | 15 | $9,788 |
| Calcitriol | 320 | $8,441 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $4,909 |
| Sevelamer Carbonate | 26 | $4,329 |
| Bumetanide | 141 | $4,190 |
| Calcium Acetate | 40 | $3,555 |
| Nifedipine ErNifedipine | 76 | $2,271 |
| Midodrine Hcl | 18 | $1,081 |
| Losartan Potassium | 81 | $900 |
| Potassium Citrate ErPotassium Citrate | 13 | $898 |
| Metolazone | 21 | $780 |
| Potassium Chloride | 32 | $676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,823 | $181,058188 claims |
| Boehringer IngelheimJardiance | $123 | $122,806101 claims |
| BayerKerendia | $14,186 | $21,76616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 325 nephrology providers in Michigan.
Other nephrology in Novi
- Alexander YevzlinAnn Arbor$1.1M
- Muwaffaq SalamehBay City$164K
- Laura MarianiAnn Arbor$150K
- Crystal Gardner-MartinLivonia$140K
- Katherine KwonSaint Joseph$111K
- Anatole BesarabDetroit$102K
- Richard CrossSaint Clair Shores$96K
- Kausik UmanathDetroit$85K
- Joel TopfRoseville$79K
- Matthias KretzlerAnn Arbor$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.